INTRODUCTION {#s1}
============

Cancer is one of serious diseases severely endangering the human health and lives. In 2012, the world had 14.1 million new cases of cancer and 8.2 million patients died from cancer \[[@R1]\]. The balance between DNA damage and repair has long been recognized to be the main determinant of individual susceptibility to disease including cancer \[[@R2]\]. The damage of DNA often caused by environmental factors such as chemicals and certain types of radiation, which, is not repaired properly would wake the stability of the genome and lead to carcinogenesis \[[@R2]\]. Thus, the host DNA repair systems play pivotal roles in maintaining the stability of human genome.

DNA repair ability plays an important role in maintaining genomic stability via several pathways. The base excision repair (BER), nucleotide excision repair (NER) and DNA mismatch repair are responsible for single strand DNA damages \[[@R3]\]; Homologous recombination (HR) and non-homologous end joining (NHEJ) repair double-strand DNA breaks (DSBs) \[[@R4]\]. *BRCA1*, breast cancer 1, early onset, plays a key role in DSBs repair via HR pathway \[[@R5]\]. Interestingly, its involvement in other types of DNA repair has since come to light, including NER, BER, and NHEJ \[[@R5]--[@R8]\]. Therefore the loss or variant of *BRCA1* may contribute to instability of gene and tumorigenesis.

The non-synonymous P871L polymorphism in *BRCA1* gene lead to the amino acid substitution of leucine (Leu, L) for proline (Pro, P) at position 871, which is part of the interaction region for the recombinase RAD51, another critical protein in HR. Thus, P871L may confer cancer susceptibility. A growing number of studies have been performed to investigate its association and cancer risk; however, the conclusions are inconsistent. The discrepancies among these studies may due to the ethnic variation and relatively small sample size. To obtain a comprehensive conclusion, we conducted this meta-analysis to systematically evaluate the association between P871L and cancer risk.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

In total, 19 articles \[[@R9]--[@R27]\] were identified according to the inclusion and exclusion criteria, which contain 24 studies with 13762 cases and 22388 controls. The study selection process was shown in Figure [1](#F1){ref-type="fig"}. A total of 1559 articles were retrieved from PubMed and EMBASE. We read the title and abstract and excluded articles that are not concern about BRCA1. Then we screened out 39 articles for further evaluation. The remaining 39 articles were reviewed carefully. 20 articles were further removed, among which 10 publications not about P871L polymorphism, 5 articles without detailed data, 3 articles concerned about prognosis or survival, 1 animal study, 1 meta-analysis. Finally, 24 studies with 13762 cases and 22388 controls from 19 articles were met the inclusion and exclusion criteria in this meta-analysis. One article \[[@R11]\] contains two populations and another article \[[@R25]\] contains four populations were divided into two studies and four studies, independently. The information of these studies, including first author, year of publication, ethnicity, cancer type, number of cases and controls, HWE and quality score for each study were presented in Table [1](#T1){ref-type="table"}. The distribution of genotypes in the controls of the studies was all in agreement with HWE except one study \[[@R12]\] due to unavailable detailed data and then only included in the dominant model.

![Flow chat of the study screening process in this meta-analysis](oncotarget-08-30587-g001){#F1}

###### Characteristics of studies included in this meta-analysis

  First author   Year   Cancer type              Ethnicity   Source of control   case   control   method               HWE     Score
  -------------- ------ ------------------------ ----------- ------------------- ------ --------- -------------------- ------- -------
  Wang           2015   gastric                  Asian       HB                  660    800       PCR-RFLP             0.204   9
  Kim            2014   NHL                      Asian       PB                  687    1700      PCR-RFLP             0.882   13
  Zhang          2013   ESCC                     Asian       PB                  540    550       PCR-RFLP             0.365   12
  Zhang          2013   ESCC                     Asian       PB                  588    600       PCR-RFLP             0.358   12
  Chen           2013   NHL                      Caucasian   PB                  459    532       TaqMan               \\      11
  Hasan          2013   breast                   Caucasian   HB                  100    100       TaqMan               0.005   4
  Wu             2013   breast                   Caucasian   FB                  335    408       TaqMan               0.354   7
  Xu             2012   thyroid                  Mixed       HB                  303    511       PCR-RFLP             0.110   8
  Xu             2012   salivary gland           Caucasian   HB                  156    511       PCR-RFLP             0.105   9
  Nicoloso       2010   breast                   Caucasian   NR                  247    185       PCR                  0.465   4
  Abbas          2010   breast                   Caucasian   PB                  3136   5470      MALDI-TOF MS         0.168   12
  Wang           2009   breast                   Asian       PB                  1004   1008      PCR-RFLP             0.626   13
  Zhou           2009   cervical                 Asian       PB                  404    404       PCR-RFLP             0.410   12
  Huo            2009   breast                   Asian       PB                  568    624       PCR-RFLP             0.757   12
  Dombernowsky   2009   breast                   Caucasian   PB                  1201   4119      TaqMan               0.187   10
  Jeffrey        2008   Glioblastomamultiforme   Caucasian   PB                  112    112       ParAllele            0.010   9
  Soucek         2006   breast                   Caucasian   HB                  305    311       PCR-RFLP             0.820   10
  Auranen        2005   ovarian                  Caucasian   PB                  722    830       TaqMan               0.331   9
  Auranen        2005   ovarian                  Caucasian   FB                  310    395       TaqMan               0.900   11
  Auranen        2005   ovarian                  Caucasian   PB                  299    781       TaqMan               0.823   10
  Auranen        2005   ovarian                  Caucasian   PB                  297    905       TaqMan               0.333   10
  Robert         2005   ovarian                  Mixed       PB                  305    388       TaqMan               0.141   11
  Dunning        1997   breast                   Caucasian   PB                  801    572       ASOs hybridisation   0.805   9
  Dunning        1997   ovarian                  Caucasian   PB                  223    572       ASOs hybridisation   0.805   7

Abbreviations: HB, hospital-based; PB, population-based; CB, center-based; FB, family based; NR, no record; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; ESCC, esophageal squamous cell carcinoma; NHL, non-hodgkin\'s lymphoma

Meta-analysis results {#s2_2}
---------------------

As shown in Table [2](#T2){ref-type="table"}, significant association between P871L polymorphism and overall cancer risk was observed \[homozygous model: OR = 0.89, 95%CI: 0.79-1.00 (Figure [2](#F2){ref-type="fig"}); recessive model: OR = 0.89, 95%CI: 0.80-0.99\]. Stratified analysis by ethnicity identified significant association among Asians \[homozygous model: OR = 0.70, 95%CI: 0.56-0.89 (Figure [3](#F3){ref-type="fig"}); recessive model: OR = 0.71, 95%CI: 0.58-0.86\] and mixed group (dominant model: OR = 0.81, 95%CI: 0.70-0.94; heterozygous model: OR = 0.77, 95%CI: 0.63-0.94). We further conducted the stratified analysis by control source and quality score of studies. As a result, a statistically significant association was observed in HB group (dominant model: OR=0.84, 95%CI: 0.74-0.97) and the high score group (homozygous model: OR =0.86, 95%CI: 0.75-0.97; 0.76-0.97; recessive model: OR = 0.86, 95%CI: 0.76-0.97). (Positive results were also presented in [Supplemental Figure 1-8](#SD1){ref-type="supplementary-material"})

###### Meta-analysis of the association between BRCA1 polymorphism and cancer risk

  Variable         No. of studies ^a^   Sample size ^b^   Homozygous        Heterozygous   Dominant          Recessive                                               
  ---------------- -------------------- ----------------- ----------------- -------------- ----------------- ----------- ----------------- ------- ----------------- -------
  All              24                   13762/22388       0.89(0.79-1.00)   0.001          0.99(0.93-1.06)   0.054       0.97(0.91-1.03)   0.020   0.89(0.80-0.99)   0.003
  Cancer type                                                                                                                                                        
  Breast           9                    7697/12797        1.03(0.93-1.13)   0.586          1.04(0.93-1.16)   0.032       1.04(0.95-1.15)   0.050   1.03(0.94-1.12)   0.710
  Ovarian          6                    2156/3871         1.00(0.84-1.19)   0.715          1.05(0.92-1.20)   0.256       1.04(0.92-1.18)   0.294   0.98(0.83-1.16)   0.832
  Others ^d^       9                    3909/5720         0.63(0.54-0.73)   0.604          0.90(0.82-0.99)   0.617       0.84(0.77-0.91)   0.948   0.66(0.57-0.77)   0.273
  Ethnicity                                                                                                                                                          
  Asian            7                    4451/5686         0.70(0.56-0.89)   0.006          0.98(0.90-1.07)   0.406       0.92(0.82-1.02)   0.107   0.71(0.58-0.86)   0.020
  Caucasian        15                   8703/15803        1.02(0.93-1.12)   0.579          1.05(0.95-1.15)   0.052       1.04(0.96-1.13)   0.106   1.02(0.94-1.11)   0.586
  Mixed            2                    608/899           0.80(0.62-1.04)   0.936          0.77(0.63-0.94)   0.993       0.81(0.70-0.94)   0.924   0.91(0.72-1.16)   0.933
  Control source                                                                                                                                                     
  PB               16                   11345/19167       0.89(0.79-1.01)   0.033          0.99(0.94-1.04)   0.150       0.97(0.91-1.03)   0.204   0.89(0.79-1.01)   0.015
  HB               5                    1524/2233         0.74(0.55-1.01)   0.085          0.90(0.78-1.03)   0.478       0.84(0.74-0.97)   0.352   0.79(0.59-1.06)   0.071
  Quality score                                                                                                                                                      
  High             19                   12554/20612       0.86(0.75-0.97)   0.002          1.00(0.93-1.07)   0.084       0.96(0.90-1.03)   0.050   0.86(0.76-0.97)   0.002
  Low              5                    1208/1776         1.06(0.79-1.43)   0.160          0.98(0.77-1.25)   0.093       1.01(0.78-1.30)   0.039   1.06(0.87-1.30)   0.546

^a^The number of studies included in our analysis.

^b^The number of cases and controls included in the studies.

^c^*P* value of the Q-test for heterogeneity test.

^d^Including gastric, NHL, ESCC, cervical cancer, thyroid cancer,salivary gland carcinoma and Glioblastoma multiform.

![Forest plot of the association between rs799917 and overall cancer risk under homozygous model\
For each study, the estimation of OR and its 95% CI are plotted with a box and a horizontal line. ♢, pooled ORs and its 95% CIs.](oncotarget-08-30587-g002){#F2}

![Forest plot of the association between rs799917 and cancer risk among ethnicity under homozygous model. For each study, the estimation of OR and its 95% CI are plotted with a box and a horizontal line\
≢, pooled ORs and their 95% CIs.](oncotarget-08-30587-g003){#F3}

Test of heterogeneity {#s2_3}
---------------------

Heterogeneities exist among all investigations for P871L polymorphism and overall cancer risk (homozygous: *P*~het~= 0.001; heterozygous: *P*~het~= 0.054; dominant: *P*~het~= 0.020; recessive: *P*~het~= 0.003). Thus, random-effect models were chosen to calculate the pooled ORs and corresponding 95% CIs for all genetic models. Then, a meta-regression was carried out to explore the possible source of heterogeneity by cancer type, ethnicity, control source and quality score of studies. As shown in Table [3](#T3){ref-type="table"}, we found cancer type (homozygous model: *P* \< 0.001; dominant model: *P* = 0.006; recessive model: *P* \< 0.001) and ethnicity (recessive model: *P* = 0.017) contribute to the heterogeneity in the meta-analysis, but not the control source and quality score of studies.

###### Meta-regression analysis of the main characteristics of the 24 studies

  Study characteristics   Homozygous   Heterozygous   Dominant   Recessive                                                                             
  ----------------------- ------------ -------------- ---------- ----------- ------------- ------- ------- ------------- ------- ------- ------------- ---------
  Cancer type             −0.23        −0.32,−0.14    \<0.001    −0.06       −0.14,−0.05   0.121   −0.10   −0.17,−0.03   0.006   −0.21   −0.30,−0.12   \<0.001
  Ethnicity               0.16         −0.03,0.36     0.094      −0.05       −0.16,−0.08   0.399   −0.02   −0.13,0.10    0.781   0.20    0.04,0.36     0.017
  Control source          0.21         −0.02,0.44     0.074      0.06        −0.09,−0.20   0.444   0.95    −0.48,0.24    0.182   0.19    −0.02,0.39    0.075
  Quality score           −0.22        −0.56,0.13     0.203      0.03        −0.18,−0.24   0.758   −0.03   0.24,0.19     0.787   −0.23   −0.53,0.08    0.133

Sensitivity analysis and publication bias {#s2_4}
-----------------------------------------

The influence of each individual data on the combined OR was estimated by sensitivity analysis and no significant difference was observed in all genetic models (data were not shown). The shape of the Begg\'s funnel plot showed symmetric distribution in the present meta-analysis (Figure [4](#F4){ref-type="fig"}). The results of Egger\'s test were as follows: (homozygous: *P* = 0.543; heterozygous: *P* = 0.378; dominant: *P* = 0.684; recessive: *P* = 0.332), which further provided no evidence of publication bias.

![Funnel plot analysis to detect publication bias for rs799917 by homozygous model for overall analysis\
Each point represents a separate study for the indicated association.](oncotarget-08-30587-g004){#F4}

DISCUSSION {#s3}
==========

In this study, significant association between P871L polymorphism and decreased risk of overall cancer was observed in homozygous, heterozygous and recessive model. Moreover, significant association was also found in subgroups of other cancers (a combination of gastric cancer, Non-Hodgkin lymphoma, esophageal Squamous Cell Carcinoma, cervical cancer, thyroid cancer, salivary gland carcinoma and glioblastoma multiform), Asians, mixed group, as well as high quality studies. To our knowledge, this is the first time to systematically evaluate the relevance of *BRCA1* P871L polymorphism to susceptibility of overall cancer.

The *BRCA1* gene is located on chromosome17q21 and composed of 24 exons. The *BRCA1* protein plays vital roles in homologous recombination \[[@R28]\]. Studies also support that *BRCA1* exerts its tumor suppression function through its involvement in cell cycle checkpoint control \[[@R29], [@R30]\]. The P871L, a non-synonymous SNP is located in the coding region of *BRCA1* leads to an amino acid change from proline to leucine, is a non-conservative change as proline conveys unique structural properties to the polypeptide. However, a number of studies have reported the conflicting roles of P871L for the risk of different types of cancer. For example, P871L was indicated to be associated with risk of several cancers, such as gastric cancer, ESCC and NHL \[[@R9],[@R11],[@R12]\], but not associated with cancers including thyroid carcinoma and ovarian cancer \[[@R15],[@R26]\]. And even the same kind of cancer, the results were conflicting \[[@R18],[@R27]\]. A meta-analysis conducted in 2014 including 7392 cases and 12486 controls observed no significant association between P871L and breast cancer risk \[[@R31]\]. Our meta-analysis with more subjects found no evidence of association between P871L and breast cancer risk either. Our work found marginal association between P871Land overall cancer risk. The discrepancy between overall cancer and stratified cancer types may due to sample size, study design, carcinogenic mechanism. In addition, relevance between P871L and overall cancer risk was found in Asians but not Caucasians in stratified analysis by ethnicity, this difference may be attributed to the different genetic background and environmental exposures.

In order to make the conclusion more credible, the publication bias analysis and sensitivity analysis was conducted. Funnel plots observed no evidence of obvious publication bias. The sensitivity analysis indicated that the results are strong and no single study yield obvious effects on the pooled ORs and the corresponding CIs.

However, several limitations in this meta-analysis should be noticed. Firstly, we could not perform further subgroup analyses for certain cancer types due to the relatively small sample size. Secondly, our results were based on unadjusted assessment of ORs, which might let our results suffer from potential confounding bias. Thirdly, even though there was no publication bias, we may miss some unpublished investigations due to studies with positive results were prone to be published. Last, the heterogeneity was existed and thus we performed the random-effects model to obtain the wider CIs, which might weaken the reliability of conclusions.

In conclusion, this comprehensive meta-analysis suggests that *BRCA1* P871L polymorphism may be associated with decreased susceptibility to cancer. However, due to the limitations of the meta-analysis, well-designed, large-scale studies will be needed to confirm these findings.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched the PubMed and Embase databases without language limitations for all related papers using the following terms: "*BRCA1* or P871L", "polymorphism or variant or variation", "cancer or carcinoma or tumor or neoplasm" (up to May 20, 2015). In addition, the references of all retrieved articles were manually searched for other related articles.

Inclusion /exclusion criteria {#s4_2}
-----------------------------

Every study included in the meta-analysis is accorded with following inclusion criteria: (1) case-control studies; (2) evaluating the association between P871L polymorphism and cancer risk; (3) and sufficient information for calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Exclusion criteria: (1) review articles; (2) case reports, or case-only studies; (3) studies that estimated the risk of prognosis.

Data extraction {#s4_3}
---------------

All data were extracted from the included studies by two authors (Miao and Yu) independently. The following information was collected from each study: first author\'s surname, year of publication, cancer type, ethnicity, control source, sample size, genotype methods and genetic distribution of cases and controls. Cancer types were classified as breast cancer, ovarian cancer and others ("others cancer type" group including cancer subgroups that contained less than three individual studies). All subjects were categorized as Caucasian, Asian and mixed. All eligible studies were categorized as population-based (PB), hospital-based (HB) and family-based (FB) according to control sources. We assessed the quality of each study according to assessment criteria ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}) and defined as high (quality score≥ 9) and low (quality score \< 9) \[[@R32]\]. Disagreements were solved by full discussion until consensuses were reached.

Statistical methods {#s4_4}
-------------------

Crude ORs with the corresponding 95% CIs were used to estimate the association between P871L polymorphism and cancer susceptibility. We used homozygous (TT vs. CC), heterozygous (CT vs. CC), dominant \[(TT/CT) vs.CC\] and recessive models \[TT vs. (CC/CT)\] as the models. The stratified analysis was performed by cancer type, ethnicity, control source and quality score of studies.

Z-test was used to determine the statistical significance of pooled ORs. Hardy-Weinberg equilibrium (HWE) was examined by Chi-square test based on the genotype distribution among controls. Heterogeneity was analyzed using the Chi-square based Q-test. When no heterogeneity exist (*P\>*0.10 for the Q-test), the fixed effect model was performed to estimate the combined OR \[[@R33]\]. Otherwise, a random effect model was used to calculate the pooled OR \[[@R34]\]. In addition, the heterogeneity was quantified by the *I*^2^ statistics and a larger *I*^2^ value indicating a greater heterogeneity \[[@R35]\]. Sensitivity analysis that used to evaluate the effect of data from each study on pooled ORs was performed by sequential deleting a single study each time. Publication bias among the literatures was evaluated by Begg\'s funnel plot and Egger\'s test \[[@R36]\]. STATA 11.0 software (Stata Corporation, College Station, TX) was used to perform all statistical tests, all the *P* values were two-sided test and *P*\< 0.05 was considered statistically significant.
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